US Drug Recall Register
Class III · Low risk Terminated Initiated Nov 25, 2014 (12 years ago)

Dacarbazine

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Discoloration: Reconstituted solution may appear pink instead of colorless to pale yellow when stored per the labeled conditions.

What was recalled

Dacarbazine, Injection, USP, 200mg, vials packaged in individual cartons, Rx only, Manufactured by Hospira Australia 1 Lexia Place, Mulgrave, Victoria Australia 3170. NDC 61703-327-22.

Recalling firm
Hospira Inc.
NDC code
61703-327-22
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0313-2015

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Dacarbazine recalls

See all
Class II · Moderate risk Terminated

Dacarbazine for Injection USP

Reason Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Teva Pharmaceuticals USA NDC 0703-5075-01 D-0271-2021
Class II · Moderate risk Terminated

DACARBAZINE 680 MG in 250 ml NS

Reason Lack of Assurance of Sterility

Infusion Options, Inc. D-1763-2019
Class II · Moderate risk Terminated

Dacarbazine active pharmaceutical ingredient packaged in varying…

Reason Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Attix Pharmaceuticals D-609-2015